NCT03415711 - PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2017

Primary Completion Date

April 24, 2019

Study Completion Date

April 24, 2019

Conditions

Ulcerative Colitis

Interventions

DIETARY_SUPPLEMENT

VSL#3®

VSL#3® 450 billion sachets

DRUG

Mesalamine

Mesalamine 2.4 g/day in once daily administration.

DRUG

Placebo

sachets with maltose, cornstarch and dioxide

Trial Locations (1)

Istituto di Medicina Interna CIC Columbus Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore, Roma